FDA Accepts Mesoblast's Resubmission of the Biologic : vimar

If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old...

Related Keywords

Japan , China , Australia , United States , Lima , Peru , Singapore , Australian , Silviu Itescu , Steve Dabkowski , Paul Hughes , Linkedin , Twitter , Marrow Transplant Research , Drug Administration , International Blood , Australian Securities Exchange , Company Biologics License Application , Marrow Transplantation Group , Oncologic Drugs Advisory Committee , Mesoblast Limited Nasdaq , Corporate Communications Investors , Office Of Therapeutic Products , Worldwide Network For Blood , Mount Sinai Acute Gvhd International Consortium , United States Food , Therapeutic Products , Biologics License Application , Prescription Drug User Fee Act , Mesoblast Chief Executive Silviu , Priority Review , Mount Sinai Acute , Mesoblast Limited , Blood Bone Marrow Transplant , Worldwide Network , Activity Report , Marrow Transplant , Glucocorticoid Refractory Acute Graft Versus Host , Private Securities Litigation Reform Act , Australian Stock Exchange Msb Ax ,